Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 74.00 GBp
Change Today -3.00 / -3.90%
Volume 364.3K
AGL On Other Exchanges
As of 12:20 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

angle plc (AGL) Snapshot

77.00 GBp
Previous Close
77.00 GBp
Day High
77.00 GBp
Day Low
73.50 GBp
52 Week High
09/25/14 - 97.50 GBp
52 Week Low
01/26/15 - 53.75 GBp
Market Cap
Average Volume 10 Days
-0.05 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for ANGLE PLC (AGL)

Related News

No related news articles were found.

angle plc (AGL) Related Businessweek News

No Related Businessweek News Found

angle plc (AGL) Details

ANGLE plc, a medical diagnostic company, provides cancer diagnostics and foetal health products, and management services primarily in the United Kingdom. The company’s lead product includes Parsortix cell separation device, which captures very rare circulating tumor cells in cancer patient blood. The resulting liquid biopsy (simple blood test) enables the investigation of mutations in the patient’s cancer for personalized cancer care. ANGLE plc was founded in 2004 and is based in Guildford, the United Kingdom.

28 Employees
Last Reported Date: 07/22/14
Founded in 2004

angle plc (AGL) Top Compensated Officers

Founder, Group Chief Executive and Director
Total Annual Compensation: 458.0K GBP
Finance Director, Company Secretary and Direc...
Total Annual Compensation: 153.0K GBP
Compensation as of Fiscal Year 2014.

angle plc (AGL) Key Developments

EKF Molecular Diagnostics Collaborates with ANGLE

EKF Molecular Diagnostics has agreed a collaboration with ANGLE, to investigate the combination of ANGLE's Parsortix circulating tumour cell (CTC) harvesting platform with EKF Molecular's PointMan DNA enrichment technology as a liquid biopsy. If successful, the resulting simple blood test could enable the investigation of unexpected ultra-low level mutations in a patient's cancer for personalised cancer care. The collaboration will initially work on colorectal cancer and then expand to cover other cancer types. CTCs will be harvested from cancer patients' blood using ANGLE's Parsortix system and then analysed using PointMan DNA enrichment technology to identify genetic variation in the cancer. Both EKF Molecular Diagnostics and ANGLE believe that the combination of the Parsortix system with PointMan technology may be advantageous for two reasons. Firstly, the PointMan system preferentially amplifies variant sequences of interest whilst suppressing amplification of the wild type i.e. normal DNA. As a result, it has the potential to identify all mutations in gene sequences associated with clinical utility of targeted cancer therapies. In contrast, competing genetic analysis systems generally amplify only those areas which may be predicted to be mutant and therefore may miss unexpected mutations. Secondly, PointMan is highly sensitive with the ability to work with very low levels of target material, potentially as low as one CTC. The high purity of the Parsortix harvest (low white blood cell contamination) and its epitope independence may enable the combined system to be widely deployed across different cancer types and stages of disease. If the collaboration is successful, EKF Molecular Diagnostics and ANGLE will explore ways to offer their respective systems as a combined solution addressing first the pharma drug trial and research use market and then, as patient data are developed, the clinical market.

Angle Plc Announces Unaudited Consolidated Earnings Results for the Six Months Ended October 31, 2014

ANGLE Plc announced unaudited consolidated earnings results for the six months ended October 31, 2014. For the period, the company reported revenue of £288,000 against £414,000 a year ago. Operating loss was £1,613,000 against £556,000 a year ago. Loss before tax was £1,606,000 against £476,000 a year ago. Loss for the period attributable to owners of the parent company was £1,476,000 against £396,000 a year ago. Basic and diluted loss per share was £3.56 against £1.05 a year ago. Net cash used in operating activities was £1,445,000 against £747,000 a year ago. Purchase of property, plant and equipment was £153,000 against £84,000 a year ago. Purchase of intangible assets was £42,000 against £235,000 a year ago.

ANGLE Plc to Report First Half, 2015 Results on Jan 29, 2015

ANGLE Plc announced that they will report first half, 2015 results on Jan 29, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGL:LN 74.00 GBp -3.00

AGL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AGL.
View Industry Companies

Industry Analysis


Industry Average

Valuation AGL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.2x
Price/Book 6.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 25.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANGLE PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at